Abstract

Integer Holdings Corporation will publish first-quarter 2026 results on April 30, 2026 Pre-Market.

Market Forecast

Market models for the current quarter indicate revenue of 426.48 million US dollars, down 0.52% year over year, with estimated EPS of 1.19, down 3.95% year over year, and EBIT of 57.99 million US dollars, down 11.19% year over year. Forecasts do not explicitly provide gross profit margin or net profit margin for the quarter.

Based on the latest business mix, Cardio and Vascular remains the core revenue driver, while Cardiac/Neurostimulation contributes a substantial minority share; Other Markets is small and offers tactical flexibility for niche programs. The segment with the most visible growth potential is Cardio and Vascular, supported by procedure volumes and product breadth; last fiscal year segment revenue was 1.11 billion US dollars, though current-year segment-level YoY projections are not disclosed.

Last Quarter Review

In the prior quarter, Integer Holdings Corporation reported revenue of 472.06 million US dollars, gross profit margin of 27.11%, GAAP net profit attributable to shareholders of 48.61 million US dollars with a net profit margin of 10.30%, and adjusted EPS of 1.76, which increased 23.08% year over year.

Net profit rose 22.51% sequentially, reflecting stronger operational leverage and a favorable mix relative to the immediately preceding quarter. By business, Cardio and Vascular was the largest contributor at 1.11 billion US dollars last fiscal year, followed by Cardiac/Neurostimulation at 668.80 million US dollars and Other Markets at 77.75 million US dollars; the company did not disclose last quarter’s segment YoY growth.

Current Quarter Outlook

Main business: Cardio and Vascular

Cardio and Vascular remains the largest end-market and revenue anchor for Integer Holdings Corporation, benefiting from stable elective and non-elective procedure volumes across cardiology and peripheral vascular interventions. Even as the consolidated revenue outlook implies a modest 0.52% contraction year over year this quarter, this franchise is likely to act as a stabilizer due to its scale and breadth of products. The segment’s resilience typically stems from OEM program cadence and sustained demand for guidewires, catheters, and delivery systems that are integrated into key customer platforms. Manufacturing and supply-chain execution will be central to sustaining margins; any incremental productivity gains or better-than-expected customer schedules could cushion the EBIT shortfall embedded in the current-quarter estimates. Investors should also watch for commentary on pricing, input costs, and capacity utilization, which will shape the gross margin trajectory as the year progresses.

Most promising business: Cardiac/Neurostimulation

Cardiac/Neurostimulation stands out as the most promising medium-term growth vector, supported by innovation cycles in implantable device ecosystems, including leads, components, and integrated subassemblies used by leading OEMs. While quarter-specific YoY data is not disclosed, the structural backdrop remains constructive: program ramps tied to new device launches, expanding indications, and the ongoing upgrade cycle in neuromodulation and cardiac rhythm management. The near-term watch items for this quarter are program timing and inventory normalization at key customers. If replenishment orders improve, this segment could provide upside to revenue mix and margin, especially given the typically higher value-add content and engineering intensity associated with implantable and stimulation platforms. Conversely, any deferrals in OEM launch timelines would keep the revenue run-rate closer to the current consensus.

Key stock-price drivers this quarter

The stock’s movement around the print is likely to hinge on three elements: the revenue run-rate versus the 426.48 million US dollars consensus, margin commentary relative to the prior quarter’s 27.11% gross margin and 10.30% net margin, and the cadence of program awards and ramps in Cardiac/Neurostimulation. A revenue outcome in line with models but accompanied by firmer-than-anticipated margins could offset the modest revenue decline implied by estimates, particularly if management signals steady demand through the second quarter. Conversely, if EBIT tracks the estimated 57.99 million US dollars with limited visibility on margin expansion or if customers signal cautious ordering patterns, investors may stay defensive. Management’s qualitative guidance on order backlog, lead times, and capital spending priorities will also influence how the market resets full-year expectations after the first-quarter update.

Analyst Opinions

Within the January 1, 2026 to April 23, 2026 window, published coverage specifically previewing the first quarter was limited, and the prevailing stance among the available institutional commentaries is cautious, aligning with the consensus expectation for a slight revenue and EPS decline year over year. The market’s baseline framing revolves around muted top-line growth this quarter and EBIT pressure, consistent with the 0.52% revenue contraction and 11.19% EBIT contraction embedded in models. Commentary from institutions during this period focused on upcoming disclosures and conference participation rather than explicit upgrades, and the tone has leaned conservative pending confirmation of order momentum and margin trends.

The cautious skew is reinforced by the absence of fresh upward estimate revisions into the event window, with consensus holding to modestly lower year-over-year revenue and EPS. This suggests investors are looking for validation that operational efficiencies can offset any pacing softness at key customers, particularly in the Cardiac/Neurostimulation portfolio. At the same time, the setup leaves room for positive surprise if Integer Holdings Corporation demonstrates that back-half initiatives in productivity and program awards are tracking ahead of schedule. Overall, the majority view into the print is characterized by guarded expectations, with the market waiting for evidence of sequential margin carry-through and clearer visibility on OEM program ramps before recalibrating stance.